Pyridinyl modulators of γ-secretase

Details Pyridinyl modulators of γ-secretase Pyridinyl modulators of γ-secretase

2011-06-28

2011-06-28

Andres, Janet (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S277000

Reexamination Certificate

active

07968725

ABSTRACT:
The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1R2, R3, R4, R5, R6, R7, R8, and R9are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's disease.

REFERENCES:
patent: 2002/0128319 (2002-09-01), Koo et al.
patent: WO 01/78721 (2001-10-01), None
patent: WO 03/008635 (2003-01-01), None
patent: WO 2006/008558 (2006-01-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Hcaplus 1974:47782 abstract, “Pyrylium salts from pyrones and some organometallic compounds”, Krivun et. al., 1973.
Wilson et. al., “Preparation of terphenylcarboxylates for treatment of Alzheimer's disease”, Hcaplus 2007:1201441, 2007.
Patani et. al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev. 1996, 96, pp. 3147-3176.
Buchwald, H., et al. “Long-Term, Continuous Intravenous Heparin Administration by an Implantable Infusion Pump in Ambulatory Patients with Recurrent Venous Thrombosis”, Surgery 88, p. 507 (1980).
During, M., et al. “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization”, Ann. Neurol. 25, p. 351 (1989).
Eriksen, J., et al. “NSAIDs and Enanatiomers of Flurbiprofen Target Gamma-Secretase and Lower A-beta-42 in vivo”, Journal of Clinical Investigation, New York, NY US vol. 112, No. 3, (2003), XP002311406.
Evans, D., et al. “Synthesis of Diaryl Ethers through the Cooper-Promoted arylation of Phenols with Arylbornic Acids. An Expedient Synthesis of Thyroxine”, Tetrahedron Letter 39 (1998) 2937-2940.
Frautschy, S., et al. “Microglial Response to Amyloid Plaques in APPsw Transgenic Mice”, Am. J. of Pathology, VI. 52, No. 1 p. 307 (1998).
Howard, M., et al. “Acute Subdural Hematomas: An Age-Dependent Clinical Entity”, J. Neurosurgery, vol. 71, p. 858 (1989).
Hsiao, K., et al. “Correlative Memory Deficits, Aβ Elevation and Amyloid Plaques in Transgenic Mice”, Science 274, p. 99 (1996).
Ida, N., et al. “Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay”, J. Biol. Chem. 271, p. 22908 (1996).
Irizarry, M., et al. “APPswTransgenic Mice Develop Age-Related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1”, J. of Neuropathology and Experimental Neurology, vol. 56(9), p. 965 (1997).
Jensen, M., et al. “Quantification of Alzheimer Amyloid Peptides Ending at Residues 40 and 42 by Novel ELISA Systems”, Mol. Med. 6 p. 291 (2000).
Kaminski, T., et al. “Side-Chain Retention During Lithiation of 4-Picoline and 3,4-Lutidine: Easy Access to Molecular Diversity in Pyridine Series”, European J. Organic Chemistry (2003) p. 3855-3860.
Kawarabayahsi, T., et al. “Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease”, J. Neurosci. 21 p. 372 (2001).
Krivun, S., et al. “Pyrylium Salts from Pyrones and Some Organometallic Compounds”, Chemistry of Heterocyclic Compounds, vol. 9 (1973) p. 1191-1194.
Langer, R., “New Methods of Drug Delivery”, Science 249, p. 1527 (1990).
Langer and Peppas “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review”, Macromol. Chem. Phys. C23(1), 61-126 (1983).
Larner, A., “Secretases as Therapeutic Targets in Alzheimer's Disease: Patents 2000-2004”, Exp. Opinion Ther. Patents 14, p. 1403 (2004).
Lehman, J., et al. “Alterations in β-Amyloid Production and Deposition in Brain Regions of Two Transgenic Models”, Neurobiol. Aging 24, p. 645 (2003).
Levy, R., et al. “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled Release Diphosphonate”, Science 228, p. 190 (1985).
Lim, G., et al. Ibuprofen Effects on Alzheimer Pathology and Open Field Activity in APPsw Transgenic Mice, Neuroibol. Aging 22, p. 645 (2001).
Lim, G., et al. “Ibuprofen Suppresses Plaque Pathology and Open Field Activity in APPsw Transgenic Mice”, Journal of Neuroscience, vol. 20(15), p. 5709 (2000).
Marjaux, E., et al. “γ-Secretase Inhibitors: Still in the Running as Alzheimer's Therapeutics”, Drug Discovery Today: Therapeutics Strategies 1, p. 1 (2004).
Morihara, T., et al. “Selective Inhibition of Aβ42 Production b NSAID R-Enantiomer”, J., Neurochem. 83, p. 1009 (2002).
Myers, A., et al. “Use of Pseudo Ephedrine as a Practical Chiral Auxiliary for Asymmetric Synthesis”, Journal of American Chemical Society, 116 (20), p. 9361 (1994).
Peretto, D., et al. “Synthesis and Biological Activity of Fluriprofen Analogues as Selective Inhibitors of β-Amylid 1-42 Secretion”, J. Med. Chem. 48 p. 5705 (2005).
Saudek, C., et al. “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery”, N. Engl. J. Med. p. 321 (1989).
Schweisguth, F., et al. Regulation of Notch Signaling Activity, Curr. Biol. 14, p. R129 (2004).
Sefton, M., “Implantable Pumps”, CRC Crit. Ref. Biomed. Eng. 14, p. 201 (1987).
Shimizu, K., et al. “Binding of Deltal, Jagged1, and Jagged2 to Notch2 Rapidly Induces Cleavage, Nuclear Translocation, and Hyperphosphorylation of Notch2”, Mol. Cell. Biol. 20, p. 6913 (2000).
Steiner, H., “Uncovering γ-Sucretase”, Curr. Alzheimer Research 1(3), p. 175 (2004).
Tanzi, R., et al. “Twenty Years of the Alzlheimer's Disease Amyloid Hypothesis: A Genetic Perspective”, Cell, vol. 120, (2005) p. 545-555.
Vassar, R., et al. “β-Secretese Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE”, science 286, p. 735 (1999).
Wang, R., et al. “The Profile of Soluble Amyloid β Protein in Cultured Cell Media”, J. Biol. Chem. 271 p. 31894 (1996).
Weggen, S., et al. “A Subset of NSAIDs Lower Amylidogenic Aβ42 Independently of Cyclooxygenase Activity”, Nature 414, p. 212 (2001).
Xia, W., et al. “Preseilin 1 Regulates the Processing of β-Amyloid Precursor Protein C-Terminal Fragments and the Generation of Amyloid β-Protein in Endoplasmic Reticulum and Golgi”, Biochemistry 3, 16465 (1998).
Yan, R., et al. “Membrane Anchored Aspartyl Protease with Alzheimer's Disease β Secretase Activity”, Nature 402, p. 533 (1999).

Affiliated with

Also associated with

Rating

Pyridinyl modulators of γ-secretase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridinyl modulators of γ-secretase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridinyl modulators of γ-secretase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2650733